Evaluation of [225Ac]Ac-PSMA-617 vis-a-vis Rechallenge [177Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario
{{output}}
Introduction: A subset of prostate cancer progresses to aggressive state of metastatic castration-resistant prostate cancer (mCRPC), wherein multiple therapeutic options demonstrate limited success rates. In this observational st... ...
